Evidence map›Paper›PMID 42392260›Full record

ArticleThe American journal of pathology2026

MYC Is Functionally Required in Both Normal and Neoplastic Meibomian Glands.

Isabella Boyack, Autumn Berlied, Su-Chan Lee, Ashley A Campbell, Charles G Eberhart, Cornelia Peterson

Abstract read
In one paragraph

Article in The American journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Isabella BoyackDepartment of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts.
Autumn BerliedDepartment of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts.
Su-Chan LeeDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ashley A CampbellDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Charles G EberhartDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: ceberha@jhmi.edu.
Cornelia PetersonDepartment of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts; Department of Ophthalmology, School of Medicine, Tufts University, Boston, Massachusetts. Electronic address: cornelia.peterson@tufts.edu.

Funding

Cross-Disciplinary Research Training for Veterinary StudentsT35OD033655 · OD · TUFTS UNIVERSITY BOSTON · PI Cheryl A London, Kelly Ann Metcalf Pate · 2022 to 2026
$459k
Investigating the Role of MYC in Meibomian Gland OncogenesisK01OD034451 · OD · TUFTS UNIVERSITY BOSTON · PI Cornelia Ward Mary Peterson · 2024 to 2026
$380k
NIH HHS K01 OD034451NIH HHS T35 OD033655
6 · The paper itself

Abstract

Despite the clinical importance of the meibomian gland (MG), the mechanisms controlling its proliferation and differentiation remain unclear. Ocular adnexal sebaceous carcinoma (SebCA), an aggressive malignancy that most often arises from the MG, lacks well-defined oncogenic drivers, but high MYC expression has been demonstrated in both tumors and primary human cell lines. This study evaluated the ongoing dependence of MYC in the MG. MYC-modulated murine MGs were evaluated using histopathology, morphometry, immunohistochemistry, and quantitative PCR. Viability, differentiation, and proliferation were evaluated in vitro, clonogenic potential was assessed by quantifying anchorage-dependent colony formation, and MYC expression was determined using enzyme-linked immunosorbent assay and quantitative PCR. MYC-inhibited murine MGs exhibited significantly reduced cytoplasmic volume with diminished proliferation and increased apoptosis with altered lipid droplet formation relative to contralateral control eyelids. SebCA viability and clonogenicity were significantly impaired by MYC inhibition, and proliferation was significantly reduced in all cells following incubation with MYCMI6. MYCMI6 also showed the most prominent suppression of canonical MYC transcriptional targets of the three MYC inhibitors used. MYC concentration was significantly lower in MYCi361- and 10074-G5-treated cells relative to vehicle control, and relative MYC expression was significantly up-regulated in 10074-G5-treated SebCA01 cells. MYC stability, MYC transcriptional activity, and the MYC:MAX heterodimer may represent critical regulators of proliferation and differentiation in the MG, with dysregulation contributing to oncogenic potential.

Indexed as

Eyelid NeoplasmsMeibomian GlandsProto-Oncogene Proteins c-mycSebaceous Gland NeoplasmsAnimalsApoptosisCell DifferentiationCell ProliferationCell SurvivalFemaleGene Expression Regulation, NeoplasticHumansMiceProto-Oncogene Proteins c-myc

Identifiers

PMID42392260
PMCPMC13692165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.